- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT06922175
Nå
Retrospektiv evaluering af Cenobamats udnyttelse af sundhedsvæsenets ressourcer (HCRU) til styring af ukontrolleret fokus på anfald
The Study is an observational, retrospective study which aim is to assess cenobamate's healthcare resources utilization (HCRU) in the management of uncontrolled focal onset seizures. The amin objective is to compare the resource utilization before and after the use of cenobamate. Data from medical charts will be used and inserted into the eCRF from which the analyses will be conducted. Data from 200 patients from 10 sites in 5 countries are included.
Studieoversigt
Status
Betingelser
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
UK
-
Glasgow, UK, Det Forenede Kongerige
- Institute of Neurosciences NHS Greater Glasgow and Clyde
-
Wolverhampton, UK, Det Forenede Kongerige
- Epilepsies - The Royal Wolverhampton NHS Trust
-
-
-
-
Netherlands
-
Heeze, Netherlands, Holland
- Kempenhaeghe - Academisch Centrum voor Epilepsie
-
-
-
-
Switzerland
-
Zurich, Switzerland, Schweiz
- Department of Neurology, University Hospital Zurich
-
-
-
-
Spain
-
Barcelona, Spain, Spanien
- Epilepsy Unit - Neurology Department Valle de Hebron Hospital
-
Madrid, Spain, Spanien
- Epilepsy Unit of the Neurology Department of the Hospital Clínico San Carlos
-
Valencia, Spain, Spanien
- Consorcio Hosp. General Universitario Valencia
-
-
-
-
Germany
-
Freiburg im Breisgau, Germany, Tyskland
- Epilepsiezentrums am Neurozentrum des Universitätsklinikum Freiburg
-
Hamburg, Germany, Tyskland
- Epileptologicum
-
Kork, Germany, Tyskland
- Diakonie Kork, Epilepsiezentrum
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Adult patients affected by epilepsy with focal-onset seizures not adequately controlled after 2 or more anti-seizure medications (ASMs), due to efficacy or tolerability issues, who start a treatment with cenobamate as an adjunctive therapy (according to SmPC), in real world setting, and have at least 6 months of data on treatment and healthcare resources utilization (HCRU) (if any) prior to cenobamate starting date.
Beskrivelse
Inclusion Criteria:
- Male and female patients of any ethnic origin ≥18 years old at index date;
- Patients with a diagnosis of epilepsy with uncontrolled focal-onset seizures despite the previous treatment with from 2 to 5 ASMs who started treatment with cenobamate at index date;
- Patients presenting at least 1 seizure a month in the last 6 months prior to index date;
- Patients with at least 6 months of data coverage in the medical records prior to the index date;
- Patients with at least 12 months of data in the medical records after index date (with a maximum interval between data of 6 months).
- Patients who give the consent to the processing of personal data according to the General Data Protection Regulation (GDPR) and/or other applicable local regulation.
Exclusion Criteria:
- Patients who meet any of the contraindications to the administration of adjunctive ASMs according to their approved SmPC;
- Patients who started cenobamate within an EAP;
- Progressive neurological disease, including degenerative CNS diseases and/or progressive brain tumors;
- Patients with specific syndrome (e.g. LGS and Dravet);
- Pregnancy or lactation;
- Patients without self-judgement ability;
- Patients with substance and alcohol abuse or dependence (except for caffeine and nicotine);
- Patients participating in any pharmacological or nonpharmacological interventional study starting from 6 months before the index date.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: RETROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
|---|
|
Adult patients affected by epilepsy with focal-onset seizures
Adult patients affected by epilepsy with focal-onset seizures not adequately controlled after 2 or more ASMs (anti-seizure medications), due to efficacy or tolerability issues, who start a treatment with cenobamate as an adjunctive therapy (according to SmPC), in real world setting, and have at least 6 months of data on treatment and HCRU (if any) prior to cenobamate starting date. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines.
Tidsramme: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU, will be collected the number of epilepsy/epilepsy treatment-related hospitalizations during all the observation period |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines.
Tidsramme: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU,will be collected the length of epilepsy/epilepsy treatment-related hospitalizations during all the observation period |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines
Tidsramme: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU will be collected the number of epilepsy/epilepsy treatment-related outpatient visits (OP) during all the observation period |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related healthcare resources utilization (HCRU), stratified by early and later treatment lines
Tidsramme: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related HCRU will be collected the number of epilepsy/epilepsy treatment-related emergency room (ER) visits; |
0-12 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Tidsramme: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Switch/add-on of other ASMs |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Tidsramme: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Changes in the dose of co-ASMs |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Tidsramme: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Changes in the number of co-ASMs |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs)
Tidsramme: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on the use of concomitant anti-seizure medications (ASMs), the following data will be recorded: Time to discontinuation of ASMs |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related emergency and medical care
Tidsramme: 0-12 months
|
To evaluate the impact of cenobamate used as adjunctive therapy on epilepsy-related emergency and medical care, the number of epilepsy/epilepsy treatment related emergency care, ambulance use, the number of outpatient visits with neurologists, and the number of epilepsy specialist nurses' intervention will be collected; |
0-12 months
|
|
Effectiveness of cenobamate used as adjunctive therapy
Tidsramme: 0-12 months
|
To evaluate the effectiveness of cenobamate used as adjunctive therapy, seizure frequency at baseline and at routinely scheduled follow-up visits, till the end of observation will be collected. For comparability, seizure frequency will be extrapolated per month (28 days); |
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on epilepsy-related surgery
Tidsramme: 0-12 months
|
To assess the impact of cenobamate used as adjunctive therapy on epilepsy-related surgery the following data will be collected:
|
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on comorbidity-related healthcare resources utilization (HCRU)
Tidsramme: 0-12 months
|
To evaluate the impact of cenobamate used as adjunctive therapy on comorbidity-related HCRU, the following data will be collected:
|
0-12 months
|
|
Impact of cenobamate used as adjunctive therapy on phone calls/virtual interventions
Tidsramme: 0-12 months
|
To evaluate the impact of cenobamate used as adjunctive therapy on phone calls/virtual interventions, the number of phone calls/virtual interventions will be collected. |
0-12 months
|
|
Safety of cenobamate used as adjunctive therapy
Tidsramme: 0-12 months
|
To evaluate safety of cenobamate used as adjunctive therapy, the number, type and severity of, adverse events, adverse drug reactions will be collected. Moreover, changes in the number, type, dose of concomitant medications other than anti-seizure medications will be collected over the duration of the study. |
0-12 months
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 169(A)AV23432
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .